Long-term antipsychotic use and cardiometabolic adverse effects in adults with non-psychotic disorders: A systematic review.
Ramya Padmavathy Radha Krishnan, Monika Dzidowska, Danni Zheng et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined the cardiometabolic adverse effects of long-term antipsychotic use in adults with non-psychotic disorders. It included 13 observational studies and found that antipsychotic-treated individuals had a prevalence of weight gain (28.8-77.9%), hyperglycaemia (4.8-23.2%), and dyslipidaemia (15.8-47.5%) compared to untreated patients. Second-generation antipsychotics were associated with greater effects.
Key findings
- Weight gain prevalence in antipsychotic-treated adults ranged from 28.8% to 77.9%.
- Hyperglycaemia prevalence was between 4.8% and 23.2% in treated individuals.
- Dyslipidaemia prevalence varied from 15.8% to 47.5% among those on antipsychotics.
- A weak association was noted between long-term antipsychotic use and cardiometabolic mortality.
Why it matters
The findings underscore the potential cardiometabolic risks associated with long-term off-label antipsychotic use, which is increasingly common. Clinicians should be aware of these risks when considering treatment options.